FYI for everybody who's Outlook suddenly became borked today with blank messages. I spent 30 minutes trying to repair, reinstall, etc. 😡

Wow! Google is releasing an AI-powered skin lesion analyzer, direct to consumer. Using AI to help find answers to common skin conditions Google blog.google/technology/hea…

❗️LAG-3 antibody + Nivolumab mPFS benefit of 10.1 vs 4.6 months vs Nivolumab alone (HR 0.75, p=0.0055). Large Phase III with 714 melanoma patients. Is this finally the first new effective checkpoint target beyond CTLA-4/PD-1?! Pending ORR/OS ascopost.com/news/may-2021/… via The ASCO Post

Very insightful piece about the use of PD-L1 as a biomarker in immunotherapy trials and how a "bottoms-up" approach has led it to be used as more of a tool to increase market share rather than a strong predictor of benefit for patients.

Point #2 is critical. We have a lot of multi histology single arm Phase II likely bc easier to accrue/complete in single centers. But with ORR being uncommon in sarcoma, how do we interpret this variable PFS data in context of existing agents? How does this change practice?

First time I've seen a RCT in dogs published in CCR! And no this is not an animal model, this is actually pet dogs with osteosarcoma!

Major decision and highly controversial accelerated approval in Alzheimer's. Two phase 3 studies that were stopped midway due to futility but a subgroup analysis of one trial showed benefit. nytimes.com/2021/06/07/hea…

Great case of precision medicine in a #LMS patient we treated. ALK fusion detected, however no response to crizotinib. Patient underwent other chemo, VEGF tx with progression, considered for hospice. Decided to try 2nd gen ALK inhibitors, alectinib, with robust response.

Our new CME Series on #RareCancers launches this Friday! Don't miss out on this 1-day, comprehensive & complimentary update on #ThyroidCancer and #Sarcomas. rarecancersupdates.com Dr. jordan berlin @Blomainiac Candace Haddox, MD Nam Bui Theresa Guo, MD

Excited to announce that Current Problems in Cancer & our #OpenAccess companion title, Current Problems in Cancer: Case Reports are on Twitter! Follow Current Problems in Cancer & CPC: Case Reports for updates on the latest scientific developments published in our journals. #CurrProbCancer #CPCcasereports

Stop by booth 21127 in the ASCO exhibit hall and meet the Editor-in-Chief of CPC: Case Reports! Nam Bui #ASCO22 @OncologyAdvance #oncology #OpenAccess

Discuss your next case report with Dr. Nam Bui at ASCO. Stop by Elsevier booth 21127 today at 11:30 am CDT. Nam Bui #ASCO22 Oncology Advance #OpenAccess #oncology

Got to meet up after today’s #ASCO22 sessions with my former ⁦UC San Diego Health Moores Cancer Center⁩ co-fellows who are now academic GI Onc at UCSD and academic sarcoma onc at Stanford. So great to see old friends in person after many years apart! ⁦Nam Bui⁩

Test your knowledge with our Case of the Week! History: Breast cancer patient undergoing neo-adjuvant chemotherapy presents with tongue changes. #MedTwitter #CPCcasereports Oncology Advance UPMC Hillman Cancer Center Adam Brufsky

Our new study with Nam Bui and Kristen Ganjoo tracking #ctDNA in patients with #sarcoma treated with #immunotherapy and #cryotherapy is online now Clinical Cancer Research. doi.org/10.1158/1078-0…

I am proud that Stanford is leading the way in sarcoma research and treatment. #SarcomaAwarenessMonth Nam Bui bit.ly/3NVyeUu

#Biomarkers of response are crucial in treating patients with #SoftTissueSarcomas. Bui et al evaluate circulating tumor DNA as a biomarker and find that it represents a promising biomarker for monitoring treatment response. bit.ly/3NNqUJu Nam Bui Everett Moding, MD, PhD

SCI member Nam Bui and Greg Charville discuss the importance of next-generation sequencing in #sarcoma. bit.ly/3t2CN7V Nam Bui Greg Charville #PrecisionMedicine